Work

Characteristics, treatment patterns, effectiveness, and discontinuation rates of rheumatoid arthritis patients treated with baricitinib or other advanced therapies in Germany (RA-BE-REAL Study)

Year: 2024

Type: conference-paper

Abstract: Introduction: Baricitinib (BARI) is a Janus kinase (JAK1/2) inhibitor approved for the treatment of adults with moderate-to-severe rheumatoid arthritis (RA). RA-BE-REAL is a prospective, multinational, observational study, evaluating time until discontinuation following either BARI, biologic disease-modifying [for full text, please go to the a.m. URL]

Source: German Medical Science (German Research Foundation)

DOI: 10.3205/24dgrh155

Authors: Alten, Rieke H. E., Burmester, Gerd-Rudiger, Zinke, Silke, Sieburg, Maren, Riegel, Kathrin, Kill, Angela, Gerwien, Jens, Ogwu, Samuel, Krüger, Klaus

Institutions: Schlosspark-Klinik, Charité - Universitätsmedizin Berlin, Eli Lilly (United States)

Language: English

Topic: Rheumatoid Arthritis Research and Therapies

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W6889909243

FWCI:

Cites:

Cited by:

Related to: